Opthea is a clinical stage biopharmaceutical company committed to developing innovative therapies to help improve visual function in patients suffering with retinal diseases. Our first in class novel therapeutic called OPT-302, is a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies to improve vision in patients, many of whom respond sub-optimally or become refractory to existing treatments. Millions of people around the world suffer from impaired vision as a result of diabetes and old age. Our mission is to improve vision leading to a better quality of life. Enquiries can be directed to: info@opthea.com

Opthea

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Novartis

Information on this competitor is not available in the provided context.

Additional Competitor

Opthea Limited is a clinical stage biopharmaceutical company focused on developing and commercializing therapies for eye diseases, with a lead product candidate, Sozinibercept (OPT 302), currently under Phase 3 clinical development for wet age-related macular degeneration and diabetic macular edema.

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Opthea Limited

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 29, 2024 1:14 AM	07cda486
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 29, 2024 1:14 AM	a5c694e7
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	283f87ae
crunchbase profile	general
li profile	general	Feb 29, 2024 1:14 AM	7b9ae72b
translate crunchbase fundingrounds	general
peers	general
news basic	general	Feb 29, 2024 1:14 AM	b1efdb69
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:OPTHEA

Opthea Limited

Last Close

0.60

25/11 05:10

Market Cap

440.22M

Beta: -

Volume Today

2.07M

Avg: -